Manager TitleAgeSince
Chief Executive Officer 53 2022-08-29
Director of Finance/CFO 55 2023-05-01
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 2015-08-31
Chairman 71 2021-04-14
Director/Board Member 59 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
+0.36%+5.10%+1.04%+5.85% 48.62B
+0.92%+6.21%+408.85%+607.44% 39.86B
+1.89%+11.06%+25.75%-7.89% 33.91B
+2.38%+8.10%+21.83%+66.94% 32.32B
+1.20%+2.02%+9.79%+32.43% 24.73B
+2.51%+4.94% - - 16.63B
+2.58%+7.24%+71.03%+132.17% 15.52B
+0.99%+1.26%+13.98%+18.88% 13.63B
-1.14%+7.52%+14.75%-30.83% 13.41B
Average +1.76%+6.58%+70.87%+103.12% 26.52B
Weighted average by Cap. +1.28%+7.00%+88.55%+131.04%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock